Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosimetry of 18F-JNJ-64326067 in Healthy Subjects
NCT03581916Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F] JNJ-64326067 in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Primary endpoints: Effective Radiation Dose Following Injection of 18F-JNJ-64326067 per Organ at Day 1 and Effective Radiation Dose Following Injection of 18F-JNJ-64326067 for Whole Body at Day 1. Started Jul 2018; status: completed.
02
Drugs
[18F] JNJ-64326067
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03581916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03581916.